Table 1.
General characteristics of the included studies
| Author (year) | Country | Intervention | Controls | Sample size test/control | Gender | Mean age (range) |
Type of RAS | Follow-up(days) |
|---|---|---|---|---|---|---|---|---|
| Sharma et al (2018) [18] | India | Topical Doxycycline |
G1: 5% Amlexanox; G2: 0.1% Triamcinolone acetonide G3: Benzocaine gel G4: placebo gel |
10/40 | 50% | 26.5 | Minor | 10 |
| Thriveni et al, (2018) [17] | India | Topical Doxycycline | Placebo 100 mg (starch, lactose, sodium starch glycolate, talc, magnesium stearate) | 20/20 | NA | NA | Minor | 10 |
| Chandak et al, (2017) [19] | India | Topical Doxycycline | 0.1% triamcinolone acetonide paste | 15/15 |
M = 14 F = 16 |
15–40 | Minor | 7 |
| Vijayabala et al. (2013) [4] | India | Topical Doxycycline | Placebo 100 mg (starch, lactose, sodium starch glycolate, talc, magnesium stearate) | 25/25 |
M = 30 F = 20 |
25.14 | Minor | 10 |
| Ylikontiola (1997) [13] | Finland | Topical Doxycycline | Placebo (calcii gluconase) | 16/15 |
M = 4 F = 27 |
23–63 | Minor | 10 |
F Female, M Male, NA Not Available